Month: May 2022

Promising treatment for memory loss could be an HIV drug: Shots

Scientists have discovered that a drug used to treat HIV can help restore a special kind of memory in rats. The results are promising for people as well.

Robert F. Bucati / AP


Hide captions

Toggle captions

Robert F. Bucati / AP


Scientists have discovered that a drug used to treat HIV can help restore a special kind of memory in rats. The results are promising for people as well.

Robert F. Bucati / AP

An HIV drug – known as maravirok – may be another, unexpected, use.

The drug appears to restore a memory that allows us to link to an event, such as a wedding, with those we’ve seen there, a team reported in this week’s issue of the journal Nature.

Maravirok’s ability to improve this type of memory was demonstrated in rats, but the drug works on a brain system that is also found in humans and plays a role in a range of brain and nervous system problems.

“You could also be affected by Alzheimer’s disease, stroke, Parkinson’s and spinal cord injuries,” he said. S. Thomas Carmichael, chair of neurology at the University of California, Los Angeles, who was not involved in the study. .

Maravirok from rat

The ability to connect memories that occur at the same time is called relational memory. It usually decreases with age and can lead to severe disability in people with Alzheimer’s disease.

Alcino Silva, author of the new study and director of UCLA’s Integrative Center for Learning and Memory, says relational memory problems can occur in people who have difficulty forming new memories.

“You learn about something, but you can’t remember where you heard it. You can’t remember who told you about it,” Silva said. “These things happen more and more as we go from middle age to old age.”

Silva says scientists have long known about the existence of relational memory in humans. “What we don’t know is how the brain does it.”

This changed when Silver Lab started studying a molecule called CCR5.

In the body, CCR5 is a key component of the immune system. But in the brain, CCR5 regulates a process that helps distinguish recent memories from older ones. Without that breakup, we wouldn’t know if we met anyone at the wedding we attended last week, or at a conference that took place decades ago.

Silva doubted that the CCR5 molecule could explain why humans and rats develop memory problems related to aging.

“But we tested, and voila,” he says.

It has been shown that the level of CCR5 increases with age and the ability to link memories seems to be “off”.

Silver Lab tested the concept in rats that have a disabled form of CCR5.

These rats can attach memories created at intervals of one week, while normal rats can attach memories created within a few hours of each other.

The team then took the normal, middle-aged rat and inserted maravirak into the hippocampus, an area of ​​the brain that is important for memory.

“This drug gave you the same thing,” Silva said. “It restores memory linking.”

Possible treatment of stroke

The results are promising for the elderly and even for stroke patients, Carmichael said.

In 2019, Silva and Carmichael were among the authors of a study that showed that levels of CCR5 increased rapidly after a stroke.

In the short term, this explosion of CCR5 activates systems that help brain cells survive, Carmichael says. “The problem is that these systems are active and they limit the ability of those brain cells to recover.”

To repair long-term damage from stroke, brain cells need to make new links – a process similar to the one used to connect certain memories. CCR5 prevents this.

So Silva and Carmichael tried to kill a rat with a stroke or a brain injury. Certainly, they recovered faster than the other rats.

They then studied a group of stroke patients with genes that gave them normally low doses of CCR5. Again, this means faster recovery.

Carmichael is currently involved in a study that will test whether Maravirok can help people with stroke.

23andMe ‘Transitional’ posted a net loss of $ 217M in FY

23 and I. It reported a net loss of $ 217 million in fiscal year 2022, ending March 31, compared to 184 million the previous year.

Consumer Genetics Company also posted a $ 70 million loss in its fourth quarter, compared to $ 67 million in the fourth quarter of 2021. Of Newly acquired telehealth segment.

In the meantime, the company has pointed to that operating cost, and to increase its net profit for therapeutics-related research and development expenses.

Total revenue for the fourth quarter was $ 101 million, and $ 272 million Yearsবৃদ্ধি An increase of 14% and 11% over the same period of the previous year, respectively

23andMe estimates full-year revenue for FY 2023 to be between $ 260 million and $ 280 million, and full-year GAAP net loss to be between $ 350 million and $ 370 million.

“Fiscal year 2022 was a transitional year for 23andMe. It was highlighted by our public listing in June 2021, followed by the acquisition of the strategically important Lemonaid Health in November, now based on our planned launch of Genomic Health Services,” said CFO Steve Schoch. Earnings said during call.

Greater trend

In October, 23andMe announced it Telehealth and online prescription platform Lemonaid have signed a specific agreement to acquire Health. The deal closed in November.

The company plans to use the Lemonaid offer as part of its Genomic Health service, where customers can access their genetic information for preventive and personalized care.

“Our efforts towards consumers will now focus on building a bridge between health risk awareness and health risk and disease management with our new genomic health services,” CEO and co-founder Ann Wojciech said during the call.

“Over the next few years, we plan to focus on the direct-to-consumer self-pay market. Once we have established ourselves in the DTC market, we can look at growth in other channels. This effort started with our acquisition and integration. Lemonaid Health and their telehealth and digital pharmacy services. “

23andMe is also working to use its genetic data for research and development of new drugs. Pharma giant at the beginning of this year GlaxoSmithKline has extended their drug discovery partnership to July 2023.

On the record

“In the coming fiscal year, we plan a more prudent holistic approach to our cash use, prioritizing our next-generation genomic health care roll-out and advancing our therapeutic efforts. Schoch said in a statement.

New and Notable: What I read this week — Version 179

Weekly research

In patients with invasive breast cancer, metformin does not seem to help.

No blood test showed “long covid”.

Prevention training and mortality.

Stonehengers ate the lungs of cattle.

The gut regulates emotions in women.

New Primal Kitchen Podcast

Primal Kitchen Podcast Episode 30: Kelly Levek on Weight Loss, Blood Sugar, Cancer and Pediatric Nutrition

Primary Health Coach Radio: Kimberly Spencer

Media, Schmidia

Social media vs. “medical success” in reality.

How TRT is changing aging.

Interesting blog post

For a short time, New York was the oyster paradise on earth.

Grass crops, cattle.

Social notes

Indeed.

What could be worse than that?

Everything else

Is that really the answer?

Is this the oldest tree in the world?

The things I’m talking about and interested in

Unknown region: Genetic embryo testing (and selection) here.

Good idea: walking team for men (and women, in this regard).

Interesting article: Rebound COVID after using Pavloxid.

Surprising: More eggs, less metabolic syndrome.

Rough quote: “The weight of the animal evidence compellingly shows that it would be unethical for a pregnant or lactating person to include high linoleic oil as the only source of fat in a random diet because it will lead to optimal baby development”

The question I’m asking

What are your summer goals?

Recipe Corner

Time capsules

One year ago (May 21 – May 27)

Comments of the week

“I hate small talk, I see no benefit in it …”

– Try asking questions. This is a better way to frame.

Primary Kitchen Mayo


About the author

Mark Season is the founder of Mark’s Daily Apple, the godfather of the early food and lifestyle movement and New York Times Its bestselling author Keto Reset Diet. His latest book Cato for life, Where he discusses how he integrates the Keto Diet with his early lifestyle for optimal health and longevity. Author of many more books, including Mark Early blueprintWho was credited with turbocharging in 2009 for the growth of the early / Paleo movement. After three decades of research and education on why food is a key ingredient for achieving and maintaining optimal well-being, Mark started Primal Kitchen, a real-food company. Which makes Primal / Paleo, Keto and Hole30-friendly kitchen staples.

Click here if you want to add an avatar to all your comments!

Study: VR Therapeutic Reduces Pain Intensity in Long-Term Compared to Sham Apps

A virtual reality therapeutic program reduces pain intensity after six months compared to a sham app, According to a published study JMIR.

The study was sponsored by AppliedVR and its RelieVRx system, formerly known as EaseVRx, have been used to evaluate its long-term effectiveness for people with chronic low back pain (CLBP). This follows previous research that analyzed the submerged eight-week program, comparing it to a 2D sham experience immediately after treatment.

The researchers sent the survey to 188 participants one, two, three and six months before, after and after treatment. Six months after treatment, they found an average change in pain intensity of -31.3% in the VR group, compared to -15.9% in the Sham group. More than half of the VR groups met the threshold for moderate clinical significance, whereas 25% of the SHAM group met that level.

Meanwhile, 38% of RelivRX cohorts have achieved substantial clinical significance, whereas only 13.2% of the Shyam group did.

Studies have also shown that VR interventions improve pain-related interventions with activity, stress, and sleep. Although the differences between the two groups were statistically significant for physical function and sleep disturbances, they were not clinically significant.

“Collectively, the results support the 6-month analgesic efficacy of a fully automated, 8-week, home-based VR program for CLBP,” the study authors wrote.

“Recent meta-analyzes of VR point to a lack of high-quality efficacy studies for chronic pain other than physical rehabilitation programs. To our knowledge, our investigations into the enhanced effectiveness of VR involve the first home-based pain management. Physical rehabilitation.”

Why it matters

The researchers noted some limitations with the study, including low levels of depressive symptoms among participants and reliance on self-reported outcomes. Although the study was double-blind, most participants assumed they belonged to a group, suggesting that blindness did not work.

The sample included mostly white female participants with some college education, so it may not apply to people from other backgrounds. However, researchers examined whether socioeconomic status (SES) affected participants’ engagement.

“While our experiments on the effects of SES on user engagement may be subject to preliminary and selective bias, we have found equivalence between EaseVRx and lower and higher SES individuals. These data potentially refute the notion that a high-tech digital treatment, As with VR, low SES may be unlikely in individuals and suggests that digital therapeutics, such as EaseVRx, present an opportunity to reach CLBP patients in historically underdeveloped areas, “he wrote.

Greater trend

VR applied CLBP received FDA De Novo clearance in November to market its VR system for treatment. The company announced $ 36 million in Series B funding in November after raising $ 29 million in Series A before 2021.

Other companies are focusing on using virtual reality to manage chronic pain. In July, XRHealth Launched a program aimed at tackling pain management. Japanese medical device maker Jolly Good announced late last year that they plan to study using VR for chronic pain. It also offers VR courses for medical training.

The rate of covid may be much higher than reported. How bad is the current wave? :

On May 17 in New York City, people walk past a coveted testing site. New York’s health commissioner, Dr. Ashwin Bhasan, has moved from a “moderate” COVID-19 alert level to a “high” alert level in five boroughs after the number of cases increased.

Spencer Platt / Getty Images


Hide captions

Toggle captions

Spencer Platt / Getty Images


On May 17 in New York City, people walk past a coveted testing site. New York’s health commissioner, Dr. Ashwin Bhasan, has moved from a “moderate” COVID-19 alert level to a “high” alert level in five boroughs after the number of cases increased.

Spencer Platt / Getty Images

The case of COVID-19 is on the rise again The United States sees an average of more than 100,000 new cases reported nationwide each day. This is almost double the rate a month ago and four times more than this time last year.

And the actual number of cases is probably much higher than that, according to health officials. Because many people now rely on indoor and outdoor testing, “we are clearly reducing the number of infections,” White House COVID-19 Response Coordinator Dr. Ashish Jha told reporters at a recent COVID press briefing. The trend of hospital admissions is also on the rise, though slowly in most places.

Yet in most places, health officials have not called for any new COVID restrictions. So how big a wave, really? And should you do something about it?

Measure the actual number of infections

The official undercounting of the case is not exactly a new issue. At the onset of the epidemic, many cases could not be detected because tests were unreliable and supplies were limited.

Jeffrey Shaman, an infectious disease specialist at Columbia University, said, “We saw in March 2020 – early – that one in 10 people, probably one in 12, had been infected,” said Jeffrey Shaman, whose lab worked to model the actual number of infections.

A very preliminary research effort to find out how many people became infected in the community involved testing resident samples for SARS-CoV-2 antibodies. That method didn’t work as the epidemic progressed, Shaman explained, because antibodies decrease over time after infection and because vaccines complicate the antibody picture.

Shaman’s research group has focused on using models to estimate “confirmation rates” – part of the actual transmission that is being captured in official case calculations. These rates have fluctuated – by the end of 2020, they estimate that one in four cases is being counted. It was close to one in six when Omicron grew.

Now with the advent of rapid testing at home that is not reported to health departments, Shaman thinks the actual number at the ballpark could be eight times higher than the number of cases. In other words, instead of 100,000 new cases per day, the actual number could be 800,000 cases per day.

Take that guess with a huge grain of salt, he advises. Getting a firm handle on the current confirmation rate is getting harder.

The Ellume COVID-19 home tests can be seen at a CVS in the vicinity of the Navy Yard in Washington, DC, where senior citizens receive free tests that are covered by Medicare on Monday, April 4th.

Tom Williams / CQ-Roll Call, Inc. via Getty Images


Hide captions

Toggle captions

Tom Williams / CQ-Roll Call, Inc. via Getty Images


The Ellume COVID-19 home tests can be seen at a CVS in the vicinity of the Navy Yard in Washington, DC, where senior citizens receive free tests that are covered by Medicare on Monday, April 4th.

Tom Williams / CQ-Roll Call, Inc. via Getty Images

Wastewater monitoring sites across the country reinforce the notion that the virus is on the rise. More than half of the sites have seen a “slight increase” in virus levels, according to the CDC, although the system does not cover the entire country and is not yet set up to provide an ongoing estimate of the actual number of cases outside the official count. .

All of this is a predictable consequence of simple, ubiquitous home testing, says Gigi Gronval, a senior scholar at the Johns Hopkins Center for Health Security.

“People have that information at their fingertips to be able to get the results they need so they can work on it immediately – it’s absolutely valuable,” he says. But it also comes at the cost of data, “and so you have to assume that there are more cases than reports.”

The next wave could be even worse

As an epidemiologist, this uncertainty is not ideal, says Caitlin Jatelina, associate professor at the University of Texas Health Science Center, who wrote the newsletter for your local epidemiologist. And even if the case count is much higher than their attendance, the healthcare crisis may not be as high this summer as it was earlier, he said.

As the weather warms up and people spend more time outdoors, “infections are much less likely to be caused by outside ventilation,” he says. Also, after a massive wave of infections from the Omicron variant, he says, “we have such a high level of infection-induced immunity that we have a very high immunity wall,” some CDCOs have speculated. Basically, if someone has a recent infection, they are less likely to be re-infected, so the virus does not spread as much or make people sick.

One of the reasons for the country’s current population-level immunity is that it makes sense for policymakers to refrain from introducing mitigation measures for the time being, says Mackiez Bonnie, a professor of biology at the Center for Infectious Diseases Dynamics in Penn State.

“It simply came to our notice then [and] The political capital that we want to save when we really need it, “he said.

He predicts that more dangerous waves are coming in autumn and winter. That’s when he thinks health officials should start ramping up “a set of new measures that will probably be needed to reduce the number of cases,” he explained.

Jatelina agrees that the country is unlikely to take big steps at the moment. “I don’t see a change in policy until another omikron-like event or a massive mutation of the virus,” he says.

Find out what’s going on with the virus wherever you are

While public health officials are not raising concerns about the rise in cases, health researchers agree that the current, partially invisible wave of certain people should be noted: older people who have not recently been vaccinated or increased.

“It’s a low hanging fruit here,” Jatelina said. “Just get the vaccine. Go get your booster. Don’t worry too much about it.” About one-third of people over the age of 65 who are eligible for a booster have not received one according to the CDC’s Vaccine Tracker – despite clear evidence it reduces the risk of hospitalization and death.

High-risk individuals should generally be more cautious if the case is high. But with so much data missing from official census reports from health agencies, how do you know how bad the COVID infection is in your community?

You can watch meteorologists on TV while predicting storms but keep your feet outside to look up at the sky, just as public health experts say it’s smart to tune in to both official and fictional signals of growing cases.

Keep an eye on the case count (knowing they are capturing part of the real case there), and hospitalization, and listen to the public health officials. But also pay attention to texts from friends and colleagues who tell you they got COVID-19.

“Those anecdotal evidence can also be useful in making decisions,” Jatelina said. If there is a sudden spike, you may know that more viruses are spreading where you live.

Another tip to look for: If your workplace or children’s school has surveillance surveys – this is a regular test for everyone, even those who have no symptoms – which can be really helpful in keeping a pulse on what’s happening with the virus locally.

“Where I am in Miami-Dade County, municipal employees may still need regular checkups and get an underlying indication of when we are growing,” said Jinji Bailey, an epidemiologist at the University of Miami.

Bailey also likes to use COVID-19 hospital admission data as a proxy for what is happening in her community.

“I look at my local hospital admissions, and if they start ticking upwards, I change my behavior accordingly – I’ll pay a little more attention to the mask, I’m going to pay a little more for what indoor spaces I want to be and how often Focus a little more on what I’m going to do, “he says

Jatelina uses the case count trendline to make decisions for her own family. “My ears started ringing [when there’s] Over the last two weeks there has been an increase of more than 50-75%, “he says. If you look at the case trend line, if the line is” just start crawling slowly, that’s fine, but if the acceleration is faster and faster, then I have something I think so. “

Then there’s a raincoat for weather forecasting – for example, getting your vaccine protection, or boosting if you’re not up-to-date. Although it is easier to make an appointment at a pharmacy, less than half of Americans who received their initial vaccine have not yet received the first booster that was approved in the fall. And now a second booster is available for anyone over 50.

Outside of vaccination, if the virus is now spreading too far in your community, anyone with high-risk due to age or underlying condition – or with someone – would be wise to dial up personal COVID-19 warnings: about time in public spaces inside selected homes and Wear a high quality well-fitting mask when you do this.

Roundup: Telehealth platform for endometriosis launched in Malaysia, India

Bayer has launched a telehealth platform for endometriosis in Malaysia

Pharmaceutical firm Bayer has partnered with digital health company DoctorOnCall and the Malaysian Endometriosis Association (MyEndosis) to launch a telehealth platform dedicated to endometriosis.

Endometriosis, a condition that affects one in 10 women worldwide, when the endometrium grows into other tissues or organs outside the womb.

The new telehealth service will provide online consultation with obstetricians-gynecologists from DoctorOnCall. For three months from June, patients will be given free teleconsultation.

“As more and more women in Asia are affected by this condition, we see a lot of significance in working with Bayer to launch this first dedicated endometriosis platform in Malaysia,” said DoctorOnCall COO Chiak Tang.

“Telehealth platforms are a powerful tool and a way to educate women about endometriosis, empowering them to express their pain and make quick decisions by making informed decisions about their condition,” said Surita Mogan, president and founder of Myendosis.

“With the increasing use of digital health platforms, especially since the COVID-19 epidemic began and as more people become digitally aware, we see the importance of tapping telehealth as an asset to benefit physicians and patients to improve the medical management of endometriosis,” Yamini said. The main divisions of the country divisions of Malaysia, Singapore and Brunei also commented.


NHA upgrades the Health ID app

The National Health Authority of India has launched an upgraded version of its Health ID app.

Formerly National Digital Health Mission’s Health Records, the revised Ayushman Bharat Health Account (ABHA) mobile app in the Google Play Store has a new user interface and an additional functionality that allows users to easily access their health records via their smartphones.

U through the appsers mainly create their health ID address which can be Attached to their 14-digit ABHA number.

The updated version now allows them to upload their own paper health records as well as share these health records, such as diagnostic reports, prescriptions and immunization certificates, on ABDM’s network of healthcare providers.

Other new features of the app include the option to edit the profile; Link and unlink ABHA number from Health ID address; And login via face and other biometric authentication.

A QR code scan The function to quickly register for any ABDM-compliant health benefits will come later in the app.


Telehealth platform adds PERDIM doctors to DoctorOnCall’s network

Malaysia’s digital health platform DoctorOnCall Pertubuhan has signed a memorandum of understanding with Doktor-Doktor Islam Malaysia or PERDIM, an organization of Muslim general practitioners in Malaysia.

The agreement adds PERDIM doctors to DoctorOnCall’s network of healthcare providers. They will be able toap by the platform’s extensive consumer base List their services, such as teleconsultation and home monitoring.

At present, DoctorOnCall has over one thousand physicians serving about 700,000 patients.

DoctorOnCall integrates healthcare products and services offered by its partner healthcare providers and professionals into a single platform. According to its director and co-founder Hajwan Najib, the company is committed to building a network of healthcare providers across Malaysia to make healthcare more accessible.

PERDIM President Dr Boi Saidi bin Abdul Razak added that their partnership would “help unlock new possibilities for medical professionals in providing healthcare”.


Intelligentex, Taiwan Life’s partner to provide telehealth services for international travelers

Hong Kong-listed health technology company IntelliCentrics has signed a memorandum of understanding with insurance company Taiwan Life Insurance Co. to provide online healthcare services to Taiwanese nationals traveling abroad.

IntelliCentrics claims that international travelers create a “huge, incomplete market” where individuals also need access to healthcare while abroad.

Its partnership with Taiwan Life will provide health advice to travelers in Taiwan through the IntelliCentrics online platform.

According to a press release, tHey will tap local partners, including EUHEL, the telehealth provider, to support their new healthcare.

The telehealth service will be launched after the partners explore more mutual benefits and get the necessary government approval.


DOC2US Watson powers Malaysia’s new telehealth service

Watson, a Malaysian telemedicine provider and DOC2US health and beauty retailer, has entered into a strategic partnership with Malaysia to connect its network of doctors with the next consumer base.

The partnership will give Watsons customers access to online health counseling with DOC2US doctors through the Watsons Malaysia mobile app.

It also allows them to receive e-prescriptions, which are distributed from selected Watsons stores, said Carin Lowe, managing director of Watson Malaysia.

For Dr. Raymond Choy, CEO and co-founder of DOC2US, their tie-up with Watsons is a step towards bridging the gap between the medical and pharmaceutical communities.

“For most patients, the first point of their care is usually the pharmacy,” he said. He added that pharmacies are also where digital health can help both pharmacists and physicians overcome barriers and serve more patients.

Clinical trial technology company uMotif International has scored যেতে 22.5M to continue

Patient data capture and clinical trial technology company uMotif announced Wednesday that it has secured 25.5 million from a fund managed by Athyrium Capital Management.

Raised London based company 2020 5 million in a Series A in 2020 and £ 2.4 million in 2018.

What does this mean?

uMotif develops software for collecting patient data for clinical trials and research, including decentralized studies. Its offers include compliance tools, electronic clinical outcome assessment (eCOA), electronic patient reporting results (ePRO) and eDiaries, and for capturing symptom information and wearable data.

What is it for?

The company will use the capital to scale and develop its platform and continue its international expansion. uMotif says it is currently used in 30 countries, and focuses on expanding its team, particularly in North America, to include sales, marketing and service delivery.

“We are delighted to welcome Atherium to support our journey to become the most patient-centered platform for research. I truly believe that clinical research must put patients first and provide more compelling research studies. We are interested in helping our sponsors, partners and – most importantly – patients to participate in the research, “CEO Steve Rosenberg said in a statement.

Snapshots of the market

In the wake of the COVID-19 epidemic that has pushed many researchers Adapting to decentralized trials, several startups are raising funds for clinical trial technology.

In April, Refai Health The Series D raised $ 220 million in funding, raising its valuation to about $ 5 billion. It offers software for study sites and sponsors to help recruit, pre-screen and enroll patients in clinical trials. Reify also provides traveling research staff and provides site setup.

Another company that focuses on decentralized trials is Curebase, which The Series B recently raised 40 million in funding. Startup tools include an app that helps patients register, sign consent forms, and access telehealth and home visits.

DCT Company Thread is also expanding its patient engagement tools. It announced in April Acquired CureClick, a platform for recruiting trial participants. Meanwhile, YPrime, a cloud-based clinical trial data management tool, unveiled plans to purchase the trial, a platform that provides support to patients so they do not drop out of the trial, in February.

Appoints Chief Marketing Officer from Transcarent Fitbit and more Digital Health

TransparentA healthcare platform focused on self-insured employers, has hired Tim Rosa as chief marketing officer.

Rosa comes in transcurrent from a health-tracking wearable manufacturer Fitbit, where he also served as chief marketing officer. It was acquired by Google in early 2021.

“TransCurrent is attracting some of the biggest consumer brands and top talent in healthcare organizations as we implement our vision to bring transparency and humanity to health and care,” CEO Glenn Toolman said in a statement.

“His experience in launching and scaling world-class brands and influential healthcare services will be important as it drives consumer engagement worldwide as TransCurrent continues to expand our offer to provide more members with the health and care experience they deserve. I couldn’t be more excited to welcome the team.” . “

Raised transparent Series C financed জান 200 million in January, and recently announced a new behavioral health program.


Healthcare Data Analysis Company Komodo Health has appointed Dr. Ashwin Chandrakantan as Chief Operating Officer, in addition to his role as Chief Medical Officer.

Chandrakantan has worked in Komodo since 2016. He has previously worked at McKinsey, Google’s Global Product Operations and Strategy Unit and consulting firm.

“Komodo is known for its diverse technology strategy, but also for the business discipline we have brought to our market,” Komodo co-founder and president Webb Sun said in a statement.

“With a proven track record of leading Commodore’s commercial, product, clinical and customer functions, we are thrilled to expand Dr. Chandrakantan’s leadership role, where he will relentlessly focus on our mission to reduce disease burden as we prepare for the company’s next growth.” . “

Komodo raised ই 220 million in Series E funding in March last year. It announced that it had acquired BreakAway Partners, a life science market access software company, last July.


EHR and provider technology company Athenahealth has appointed John Hoffman as chief financial officer following the retirement of Louis Burgen last month.

Hoffman came to AthenaHealth from the transportation and logistics software company Omnitrax, where he was CFO. He also served as CFO at marketing data firm InfoGroup, now rebranded as Data Excel.

“I am honored to be part of Athenahealth’s incredible team,” Hoffman said in a statement. I look forward to working with many dedicated and talented people in the company to further realize the company’s goals. Transformation of healthcare delivery. “


Clinical Trial Technology Company YPrime has announced that it has appointed two new members to its executive team, Mohan Ganesan as Chief Financial Officer and Alison O’Neill as Chief Operating Officer.

CEO Shawn Blackburn said in a statement: “It is a privilege to include these two experienced leaders in our executive team.” “We have always been about sponsors, sites and patients to ensure the best experience.

“Under Mohan’s leadership, we will be able to make strategic investment decisions that meet the growing needs of our clients and measure our business impact. The depth of Ali’s expertise allows us to continue to improve to meet our products, processes and services.” “

Imaging contrast delays testing for short-term disease

Physicians can’t figure out what’s wrong with Michael Quintos.

Mr. Quintos, 53, a resident of Chicago, suffers from persistent abdominal pain. She has been hospitalized, and her doctors have tried everything, including antibiotics, antacids, and even appendix removal. “I still don’t feel well,” Mr Quintos said.

Her doctors recommend using a CT scan with contrast, imaging that relies on a special pigment to better visualize patients’ blood vessels, intestines, and organs such as the kidneys and liver.

But a nationwide shortage of imaging agents required for the procedure – the result of a recent lockdown in Shanghai due to the covidia outbreak – has prompted hospitals to ration these tests without an emergency.

Like thousands of others in recent weeks, Mr. Quintos will not be able to test using contrast dye.

And an alternative may not be enough to determine how his illness can be treated. “You can’t get it out. It tells me you need more tools to get it out,” he said.

An estimated 50 million tests with contrast agents are performed each year in the United States, and about half of the country is affected by hospital deficits. Some are saving most of their supplies for use in emergency rooms – where quick, accurate assessments are most feared.

The shortage of a vital imaging agent is the latest example of the country’s weakness in disrupting the global supply chain and its over-reliance on a small number of manufacturers for such critical products. The Shanghai plant, which was shut down due to a lockdown, is operated by GE Healthcare, a unit of General Electric and one of the two main suppliers of iodized contrast materials. The company supplies its dyes, Omnipaque and Visipaque to the United States.

Lawmakers have expressed concern about the lack of imaging agents. “In the richest country in the world, there should be no reason to force doctors to perform life-saving medical scans to make up for the material deficiency,” said Rosa Delauro, a Democrat in Connecticut, in a statement. “We see the supply chain breaking down because the combined industries are experiencing production shortages and offshoring of American jobs in China.”

The U.S. Food and Drug Administration was notified of the dye shortage earlier this month and the agency said it was working closely with manufacturers to “help reduce the impact on patients.” Yet even though GE Healthcare said this week that the situation is improving now that the plant has reopened, deficits and patient delays could go well in the summer as faster replenishment supplies can be delivered.

Senator Patty Murray, a Democrat in Washington, is pressuring the agency to see what steps it can take to address the deficit, according to a statement from her office. He has enacted legislation with North Carolina Republican Senator Richard Burr to strengthen the supply chain.

“The epidemic continues to hit the supply chain,” said Dr. Jamie McCarthy, chief medical officer of Memorial Herman Health System, a large hospital group in Houston.

Health officials and doctors worry that short supplies and prolonged waiting for tests will exacerbate pre-epidemic delays caused by the epidemic, when hospitals were overflowing with coward patients, faced large backlogs for testing and selection procedures were canceled or postponed for months. . . Patients who have ignored new symptoms or failed to get a follow-up appointment have in many cases suffered from poor health. Some doctors report more cancer patients with advanced-stage disease as a result.

Dr. William Dahut, chief scientific officer of the American Cancer Society, said, “We are concerned about the impact of delayed, delayed or neglected screening over the past few years.

He said the lack of contrast dye in an experiment could make it more difficult to diagnose cancer, and make it harder to see if the treatment was working. “Patients may be in situations where clinical decisions are going to be negatively affected,” said Dr. Dahut.

In addition to using contrast CT angiograms to determine if patients have blood clots or internal bleeding, doctors often rely on CT scans to rule out spot infections, bowel obstruction, or cancer. Physicians are also delaying some cardiac catheterization.

Lack of mammograms and screening for lung cancer does not affect people because they do not need imaging agents, and some patients may be able to have an MRI or contrast test instead of a CT scan.

But for many others, lack leaves them destitute. “It’s definitely putting more pressure on patients,” said Dr. Shikha Jain, a cancer specialist in Chicago. “There are patients who are frustrated because scans are being delayed or canceled.”

It is difficult to estimate how long and how much the deficit will affect patient care. For healthcare workers, whose supply shortages and epidemics are taxing so relentlessly, “it feels like a never-ending marathon,” he said.

At Memorial Harmony, the system has “throttle-backed” its contrasting use for alternative methods, Dr. McCarthy said, in order to preserve its supply. The daily volume of CT scans is performed with contrast which is usually about half that, he said.

At Delaware-based hospital group Christiancare, supply shortages occurred in mid-May and “quickly became a serious problem,” said Dr. Kirk Garrett, medical director of the group’s Heart and Vascular Health Center and a former president of the Society for Cardiovascular Angiography. . When hospitals in other areas began to run out of color, they began sending patients to Christian care. “It affects our burn rate,” he said.

“We’re really worried about here,” said Dr. Garrett. Explaining why electoral procedures are being delayed, he added: “We feel we need to make these changes now to make sure we have the supplies we need to take care of our urgent needs.”

A patient who fails an exercise stress test that may indicate heart problems but is not in imminent danger will have to wait for a scan and be treated with medication. But if a patient enters the emergency room and continues to sweat with severe chest pain, an angiogram is immediately directed so that a contrast dye is needed to determine if the person has a heart attack.

“Either we fix it now, or it will be too late to save you in a few hours,” said Dr. Garrett.

Hospitals typically rely on a single supplier for their contrast agents and many facilities may have only one or two weeks of supply at hand, said Dr. Matthew Davenport, vice chairman of the American College of Radiology’s Quality and Safety Commission and a professor of Michigan medicine.

He compared the situation to the current lack of baby formula, where only a few companies serve a critical market. Dr Davenport said: “There is not much redundancy in the system.

GE Healthcare said in a statement on Monday that its supply of iodized contrast media products was increasing, although it did not provide an estimate of when the deficit would end. “We are working around the clock to expand production and return to full power as soon as possible and in coordination with local authorities,” the agency said.

“After closing our Shanghai manufacturing facility for several weeks due to local covid policy, we have been able to reopen and use our other global plants wherever possible,” the statement said.

GE Healthcare reports that the plant is operating at 60 percent capacity and will operate at 75 percent in the next two weeks. It added that it had taken other steps, such as increasing production at its plant in Cork, Ireland, and flying some shipments to the United States.

The agency also said it was distributing dyes to hospitals based on their historic supply needs, which doctors said could prevent large hospital systems from overstocking.

Braco Imaging, another producer based in Milan, said in a statement that it was also working to deliver supplies to hospitals that customers could not use for “critical emergency procedures”, according to Fulvio Reynolds Braco, the company’s chief executive. In a statement, he said Braco had also submitted a request to the FDA for possible import of an equivalent agent that had not been approved for use in the United States. The agency declined to comment on the request.

Nancy Foster, vice president of the American Hospitals Association’s Quality and Patient Safety Policy, a trade group in Washington, D.C., compared the situation with the short supply of oxygen to other treatment machines and remedies during the epidemic. The group has asked GE to share more information about the deficit.

“We need to figure out how to build a truly powerful, lean, supply system that can deliver something,” he said.

How can mass shootings be prevented? Research shows some principles can help

Protesters join a candlelight vigil for the victims of the Uvalade and Buffalo massacres on May 25 in Fairfax, VA.

Allison Bailey / Reuters Connect


Hide captions

Toggle captions

Allison Bailey / Reuters Connect


Protesters join a candlelight vigil for the victims of the Uvalade and Buffalo massacres on May 25 in Fairfax, VA.

Allison Bailey / Reuters Connect

Every mass shooting in the United States calls for better policies to prevent such tragedies. Field scientists say there is evidence that certain types of legislation can reduce deaths from mass shootings – but alternatives to this policy are not usually discussed in light of these events.

Michael Anesthes, executive director of the New Jersey Gun Violence Research Center at Rutgers University, notes that research scientists need to draw from a limited body. “Mass shooting research is a very small part of gun violence research,” he says.

That’s because less than 1% of the nearly 40,000 people killed by gunfire in this country each year are responsible for mass shootings, Anastasia explained. “These are awesome, these are all very common, and yet, that’s just the tip of the iceberg, isn’t it?”

Researchers who study gun violence tend to focus on violence, such as suicide, which is most commonly associated with death, but he adds that the whole field of gun violence research has long been neglected and under-funded.

“There’s money out there, but it’s really down a lot where it should be given the amount of injuries and deaths and the economic costs associated with gun violence,” Anastasis said. “It’s just disproportionately low funding.”

Even so, owning one is still beyond the reach of the average person.

Such a study has taken advantage of the fact that in the United States, gun laws vary from state to state. “It’s, honestly, less than ideal from a public safety perspective, but it gives researchers a chance,” said Daniel Webster, co-director of the Johns Hopkins Center for Gun Violence Solutions.

He and a number of colleagues recently analyzed more than 30 years of data on shootings in the United States that involved four or more victims. They compared the states in an attempt to quell the impact of different gun laws. “I have to admit that this is really a difficult and frank science,” Webster said.

Despite these limitations, he said, “we have found two policies that have had a significant protective effect in reducing the rate of deadly mass shootings.”

One was a requirement that a gun buyer must go through a licensing process. “The licensing process requires someone, you know, to apply directly and be involved with law enforcement agencies, sometimes with security training and other requirements,” Webster said.

Another approach that seems to reduce the death toll from mass shootings is the state ban on the purchase of large-capacity magazines or ammunition feeding devices for semi-automatic weapons.

Webster says this is intuitive, as these items allow a shooter to fire multiple shots in a short period of time without interruption. If a shooter had to stop and reload, the prey could flee or fight.

Another study of mass shootings has shown that such laws appear to have a protective effect. David Hemenway, director of the Harvard Injury Control Research Center, has been working with colleagues to examine the effects of banning large-capacity magazines on mass shootings in various states for nearly three decades.

“The states that had the ban have done much better in firing fewer shots, and the shots that have been fired are far less lethal in terms of the number of people killed,” Hemenway said.

In the wake of a mass shooting, people often argue for the need for a massive background check, Webster says. He supports that policy, but says his research does not show that it is associated with a reduction in such fatalities.

An additional general break after mass shootings, he said, was the call for a policy that makes it easier for people to carry guns so they can defend themselves. “Okay, guess what, the data doesn’t carry that at all,” Webster said. “If anything, it shows a high rate of deadly mass shootings in response to weak regulations on concealment by civilians.”

And while school systems may try to respond to the threat of mass shootings by placing police officers on site or using student drills, “as far as I know, there is no strong research on any of these issues,” Hemenway said.

Keeping guns away from young people, through age restrictions on safe storage or purchase of firearms at home, would be expected to have a protective effect, Webster said.

The public health risks associated with young people drinking alcohol have led to a ban on drinking under the age of 21, he said. But the Uvalade shooter was able to legally buy a semiautomatic rifle after his 18th birthday.

While it is admirable that age restrictions can make it harder for young adults to access weapons capable of producing a mass shot, Anastasis says, but “do we have the big data-driven resources to evaluate those policies? No, we do.” No. “

An emerging policy alternative that has some preliminary evidence behind it is to allow police officers to temporarily remove guns from people who appear to pose an impending danger. A study in California that looked at how the process was used in that state over a two-year period found 21 incidents when it was done in response to a mass shooting threat – several of these threats involved schools.

It is unknown at this time what he will do after leaving the post. A 2017 study found that guns kill nearly as many people each year as sepsis, a fatal response to infection, but funding for gun violence research was about 0.7% for sepsis.

“There’s a lot to study in the gun area, and we haven’t studied nearly enough in 25 years,” Hemenway said. “Once you scratch the surface right now about what is known, we know very little.”